Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences, Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E12.82 EPS (ttm)5.40 Insider Own0.40% Shs Outstand1.29B Perf Week1.50%
Market Cap89.33B Forward P/E10.23 EPS next Y6.76 Insider Trans-4.62% Shs Float1.29B Perf Month6.69%
Income7.07B PEG- EPS next Q1.70 Inst Own81.40% Short Float1.13% Perf Quarter-8.52%
Sales22.28B P/S4.01 EPS this Y-22.80% Inst Trans0.06% Short Ratio1.82 Perf Half Y-10.21%
Book/sh17.64 P/B3.92 EPS next Y-2.21% ROA2.40% Target Price85.15 Perf Year-14.77%
Cash/sh22.04 P/C3.14 EPS next 5Y-5.23% ROE7.40% 52W Range60.32 - 89.54 Perf YTD10.60%
Dividend2.28 P/FCF17.88 EPS past 5Y36.20% ROI19.90% 52W High-22.74% Beta1.20
Dividend %3.30% Quick Ratio3.40 Sales past 5Y21.90% Gross Margin79.60% 52W Low14.69% ATR1.92
Employees10000 Current Ratio3.50 Sales Q/Q-14.10% Oper. Margin42.00% RSI (14)59.30 Volatility1.90% 2.99%
OptionableYes Debt/Eq1.19 EPS Q/Q-22.10% Profit Margin7.10% Rel Volume1.05 Prev Close68.65
ShortableYes LT Debt/Eq1.07 EarningsFeb 04 AMC Payout180.20% Avg Volume7.93M Price69.18
Recom2.10 SMA205.45% SMA502.41% SMA200-3.54% Volume8,351,520 Change0.77%
Jan-03-19Upgrade Oppenheimer Perform → Outperform $85
Oct-26-18Reiterated Barclays Overweight $90 → $95
Oct-26-18Downgrade Piper Jaffray Overweight → Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $87
Jul-26-18Downgrade Robert W. Baird Outperform → Neutral $79
Jun-28-18Initiated Raymond James Strong Buy
May-02-18Reiterated Maxim Group Buy $94 → $89
Mar-06-18Reiterated Barclays Overweight $90 → $95
Feb-22-18Reiterated Leerink Partners Mkt Perform $83 → $80
Feb-12-18Reiterated Mizuho Buy $83 → $95
Feb-08-18Reiterated Citigroup Buy $103 → $105
Jan-26-18Upgrade Jefferies Hold → Buy
Jan-16-18Upgrade Wells Fargo Market Perform → Outperform
Dec-20-17Downgrade Credit Suisse Outperform → Neutral
Nov-30-17Upgrade Maxim Group Hold → Buy $94
Nov-13-17Downgrade Argus Buy → Hold
Nov-08-17Reiterated Mizuho Buy $77 → $83
Oct-11-17Resumed Barclays Overweight $90
Oct-05-17Initiated Oppenheimer Perform
Oct-04-17Resumed Jefferies Hold $93
Jan-19-19 12:00PM  Better Buy: Biogen vs. Gilead Sciences Motley Fool
Jan-18-19 04:12PM  These 3 Biotech Stocks Appear Poised To Beat Fourth-Quarter Forecasts Investor's Business Daily
09:15AM  Searching For A Treatment: NASH Investigational Drugs With Catalysts This Year Benzinga
Jan-17-19 04:34PM  1 Chart That Shows Why Celgene Has Been Bought Out and Gilead Hasn't (Yet) Motley Fool
10:26AM  Why Gilead Sciences Stock Sank by 12.7% in 2018 Motley Fool
08:48AM  Zacks Market Edge Highlights: Occidental, Gilead, AbbVie, AT&T and Verizon Zacks
Jan-16-19 12:28PM  Will Dividend Stocks be the Hot Stocks of 2019? Zacks
Jan-15-19 05:45PM  Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know Zacks
04:18PM  Here's How The Government Shutdown Will Affect These Medical Stocks Investor's Business Daily
Jan-11-19 07:48PM  Here's Why Verastem Tumbled 34.1% in December Motley Fool
06:11PM  NASH Space in Focus in 2019 as Firms Look to Diversify Zacks
Jan-09-19 02:04PM  Have Insiders Been Selling Gilead Sciences, Inc. (NASDAQ:GILD) Shares? Simply Wall St.
12:29PM  Value Added: 7 Top Stocks for 2019 Kiplinger
09:33AM  Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus Zacks
09:28AM  Cell therapy pioneer eyes Bay Area manufacturing American City Business Journals
Jan-08-19 04:24PM  The 9 Best Stocks of America’s Last Bear Market Kiplinger
10:03AM  Top Gainers: Union Pacific, Motorcar Parts, Nektar Rally Into Close Investing.com
06:00AM  7 Things to Expect for Gilead Sciences in 2019 Motley Fool
01:00AM  Japans Ministry of Health, Labour and Welfare Approves Gileads Epclusa® (Sofosbuvir/Velpatasvir) Business Wire
Jan-07-19 05:45PM  Gilead Sciences (GILD) Gains But Lags Market: What You Should Know Zacks
04:53PM  Biotech's big conference living up to reputation with big deals, big costs American City Business Journals
12:17PM  Why Agenus Stock Is Spiking Today Motley Fool
10:56AM  As Patent Expirations Loom, the Clock Is Ticking on AbbVie Stock InvestorPlace
10:29AM  Merck loses bid to revive $200 million Gilead verdict at U.S. high court Reuters
10:17AM  Merck loses bid to revive $200 million Gilead verdict at U.S. high court Reuters
09:54AM  Merck loses bid to revive $200 mln Gilead verdict at U.S. high court Reuters
09:09AM  Gilead (GILD) Collaborates With Yuhan for NASH Candidates Zacks
Jan-06-19 06:06PM  Better Buy: Gilead Sciences vs. Amgen Motley Fool
05:30PM  Gilead Sciences and Yuhan Corporation Announce Collaboration and License Agreement to Develop Novel Investigational Treatments for Advanced Fibrosis Due to Nonalcoholic Steatohepatitis Business Wire
11:00AM  2019 J.P. Morgan Healthcare Conference Roundup Motley Fool
Jan-04-19 06:50AM  Today's Research Reports on Trending Tickers: Prana Biotechnology and Gilead Sciences ACCESSWIRE
Jan-03-19 05:46PM  Factbox - Bristol-Myers' $74 billion Celgene buy has investors looking for next deal Reuters
02:35PM  Gilead Stock Breaks Out to Channel Resistance Investopedia
12:35PM  3 Biopharma Stocks to Buy for Their Robust Dividend Yields InvestorPlace
10:51AM  Gilead Sciences Gets a Boost After Celgene Deal Barrons.com
08:51AM  Stocks Tumble, Celgene Spikes; Apple Cripples Global Tech Stocks Investor's Business Daily
Jan-02-19 09:01AM  Gilead Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7 Business Wire
08:30AM  Biotech Rally Ahead of the Market ACCESSWIRE
Dec-30-18 08:39AM  The $35 billion race to cure a liver disease that affects 30 million Americans CNBC
Dec-28-18 05:45PM  Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know Zacks
04:52PM  Intercept (ICPT) Benefits from Ocaliva's Recovery in 2018 Zacks
10:11AM  2019 biotech preview: Money is pouring into the Bay Area and so is Big Pharma American City Business Journals
Dec-26-18 10:32AM  3 Biotech Stocks That Are Too Cheap to Ignore Motley Fool
09:34AM  Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal Zacks
Dec-24-18 09:53AM  Health Care Digest: 'Killing off' the JPM Week golden goose, a $75 million complement and more American City Business Journals
09:29AM  Mallinckrodt's Inhaled Xenon Gas Therapy Enters Phase III Zacks
09:26AM  Alexion's Ultomiris Gets Early FDA Nod for Rare Blood Disorder Zacks
08:59AM  Acorda Gets FDA Approval for Parkinson's Disease Drug Inbrija Zacks
08:39AM  Immunomedics (IMMU) in Focus: Stock Moves 6.1% Higher Zacks
Dec-23-18 09:03AM  2 Beaten-Down Biotech Stocks That Look Like Bargains Now Motley Fool
Dec-21-18 09:19AM  Agenus' Stock Up 23% on Immuno-Oncology Deal With Gilead Zacks
08:51AM  Novartis (NVS) Offers to Buy French Gene Therapy Manufacturer Zacks
08:00AM  Major Biotech Deals Making Sector Red Hot ACCESSWIRE
Dec-20-18 06:11PM  Bristol-Myers to Sell French Consumer Health Unit for $1.6B Zacks
05:59PM  Gilead Partners with Scholar Rock for Fibrotic Disease Drugs Zacks
12:48PM  Why Agenus Stock Is Soaring Today Motley Fool
09:43AM  Raymond James: Gilead In NASH For The Long Haul Benzinga
08:28AM  Agenus stock shoots up 60% after announcing drug development deal with Gilead MarketWatch
07:48AM  Gilead, Agenus sign deal to develop immuno-oncology therapies Reuters
07:30AM  Gilead And Agenus Enter into Collaboration to Develop Immuno-Oncology Therapies PR Newswire
07:30AM  Gilead and Agenus Enter Into Collaboration to Develop Immuno-Oncology Therapies Business Wire
07:30AM  Biotech Stocks Set to Breakout ACCESSWIRE
Dec-19-18 09:12AM  Vertex's (VRTX) 3rd Study on Pain Drug Meets Primary Endpoint Zacks
08:23AM  Forget bluebird bio, Amgen Is a Better Biotech Stock Motley Fool
08:01AM  Gilead Sciences and Scholar Rock Announce Strategic Collaboration to Develop Novel Therapies for Fibrotic Diseases Business Wire
Dec-18-18 07:20PM  Bristol-Myers' Label Expansion of Sprycel Gets CHMP Nod Zacks
02:01PM  Evofem Shares Up as Birth Control Gel Succeeds in Phase III Zacks
11:55AM  Biotech Stocks Gilead Sciences and Biogen Have Room to Bounce Back Barrons.com
10:20AM  Puma Biotech's Nerlynx Ups Survival in Third-Line Breast Cancer Zacks
09:15AM  What Happened With CAR-T Stocks in 2018 Motley Fool
07:17AM  3 Biotechs With Potential Blockbusters Near the Finish Line Motley Fool
Dec-17-18 05:45PM  Gilead Sciences (GILD) Stock Moves -0.69%: What You Should Know Zacks
12:28PM  5 Healthcare Stocks That Are Feeling Sick InvestorPlace
12:25PM  7 Major Pharmaceutical Stocks to Quarantine Now InvestorPlace
11:15AM  Goldman Called 2019 The Year of NASH, Others Say Not So Fast Bloomberg
Dec-16-18 09:07AM  2 Sets of Disasters Biotech Will Pay For in 2019 Motley Fool
Dec-15-18 03:49PM  Stocks That Fell to 3-Year Lows in the Week of Dec. 14 GuruFocus.com
08:03AM  3 Biotechs Gilead Sciences Could Buy in March Motley Fool
Dec-14-18 12:32PM  Mylan (MYL) Gets Favorable Ruling Against Sanofi's Lantus Zacks
10:25AM  AMAG to Acquire Ciraparantag Maker Perosphere Pharmaceuticals Zacks
07:59AM  5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride Zacks
07:00AM  Today's Research Reports on Trending Tickers: Axovant Sciences and Gilead Sciences ACCESSWIRE
Dec-13-18 09:26AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis Zacks
09:02AM  Bausch (BHC) Bids for Assets of Synergy Pharmaceuticals Zacks
Dec-12-18 10:03AM  Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate Zacks
03:17AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen Zacks
Dec-11-18 03:55PM  Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO Zacks
02:49PM  New Gilead Sciences CEO Has 'Breadth Of Experience' From Time At Roche, Says Bullish Raymond James Benzinga
02:02PM  7 Stocks That Can Lead The Market Long Term Investopedia
12:07PM  The 10 Best Marijuana Stocks to Buy in 2019 InvestorPlace
09:00AM  4 Biotech Stocks Investors Can Add to Their Portfolio in 2019 Zacks
Dec-10-18 05:45PM  Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know Zacks
04:31PM  Why CRSP Stock Has Added Layers of Risk InvestorPlace
04:13PM  Health Care Digest: Where were the women in Gilead's CEO search and more American City Business Journals
01:34PM  Gilead Sciences Names Roche's O'Day as CEO and Chairman TheStreet.com
01:14PM  Gilead Needs More Than a Steady Hand From Its New CEO Bloomberg
12:17PM  Roche's Tecentriq Gets FDA Approval for First-Line NSCLC Zacks
11:42AM  [$$] Gilead Looks Outside to Revive Growth The Wall Street Journal
10:33AM  Dont Punish Gilead Stock for Doing Its Job InvestorPlace
10:10AM  Stocks - Apple, Boeing Slip in Premarket; Gilead Sciences, Tesla, Amazon Rise Investing.com
Gilead Sciences, Inc. discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for blood cancer; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Tango Therapeutics, Inc.; AELIX Therapeutics S.L.; TARGET PharmaSolutions, Inc.; Scholar Rock Holding Corporation; and Agenus Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARTIN JOHN CDirectorDec 03Option Exercise23.6050,0001,180,0002,927,762Dec 04 08:02 PM
MARTIN JOHN CDirectorDec 03Sale71.2050,0003,560,1782,877,762Dec 04 08:02 PM
MILLIGAN JOHN FPresident and CEONov 27Option Exercise23.60280,0006,608,0001,574,306Nov 29 08:42 PM
MARTIN JOHN CDirectorNov 01Option Exercise23.6050,0001,180,0003,067,762Nov 05 07:45 PM
MARTIN JOHN CDirectorNov 01Sale69.5550,0003,477,6173,017,762Nov 05 07:45 PM
MARTIN JOHN CDirectorOct 01Option Exercise23.6050,0001,180,0003,067,762Oct 03 05:45 PM
MARTIN JOHN CDirectorOct 01Sale78.0450,0003,902,2103,017,762Oct 03 05:45 PM
MARTIN JOHN CDirectorSep 04Option Exercise23.6050,0001,180,0003,067,762Sep 06 05:24 PM
MARTIN JOHN CDirectorSep 04Sale74.1650,0003,708,0343,017,762Sep 06 05:24 PM
MARTIN JOHN CDirectorAug 01Option Exercise23.6050,0001,180,0003,067,762Aug 03 04:41 PM
MARTIN JOHN CDirectorAug 01Sale77.8550,0003,892,6503,017,762Aug 03 04:41 PM
MARTIN JOHN CDirectorJul 02Option Exercise23.6050,0001,180,0003,067,762Jul 05 08:00 PM
MARTIN JOHN CDirectorJul 02Sale70.8150,0003,540,2823,017,762Jul 05 08:00 PM
MARTIN JOHN CDirectorJun 01Option Exercise23.6050,0001,180,0003,067,762Jun 05 07:34 PM
MARTIN JOHN CDirectorJun 01Sale68.1350,0003,406,4953,017,762Jun 05 07:34 PM
Cogan John FrancisDirectorMay 04Option Exercise26.625,836155,32558,455May 08 01:59 PM
MILLIGAN JOHN FPresident and CEOMay 04Option Exercise27.0780,0002,165,6001,294,306May 08 06:29 PM
Cogan John FrancisDirectorMay 04Sale65.095,836379,88552,619May 08 01:59 PM
MARTIN JOHN CDirectorMay 01Option Exercise23.6050,0001,180,0003,067,762May 03 01:07 PM
MARTIN JOHN CDirectorMay 01Sale72.1950,0003,609,6603,017,762May 03 01:07 PM
Cogan John FrancisDirectorApr 27Option Exercise26.625,833155,24558,452Apr 30 05:39 PM
Cogan John FrancisDirectorApr 27Sale73.915,833431,11752,619Apr 30 05:39 PM
Cogan John FrancisDirectorApr 20Option Exercise26.625,833155,24558,452Apr 23 07:16 PM
Cogan John FrancisDirectorApr 20Sale73.745,833430,13052,619Apr 23 07:16 PM
Cogan John FrancisDirectorApr 13Option Exercise26.625,833155,24558,452Apr 16 06:45 PM
Cogan John FrancisDirectorApr 13Sale75.565,833440,74152,619Apr 16 06:45 PM
Cogan John FrancisDirectorApr 06Option Exercise26.625,833155,24558,452Apr 09 06:41 PM
Cogan John FrancisDirectorApr 06Sale74.475,833434,38452,619Apr 09 06:41 PM
Cogan John FrancisDirectorApr 02Option Exercise26.625,833155,24558,452Apr 04 04:23 PM
MARTIN JOHN CDirectorApr 02Option Exercise23.6050,0001,180,0003,067,762Apr 04 07:34 PM
MARTIN JOHN CDirectorApr 02Sale73.1450,0003,656,8063,017,762Apr 04 07:34 PM
Cogan John FrancisDirectorApr 02Sale74.935,833437,06752,619Apr 04 04:23 PM
Cogan John FrancisDirectorMar 23Option Exercise26.625,833155,24558,452Mar 26 06:48 PM
Cogan John FrancisDirectorMar 23Sale75.025,833437,58852,619Mar 26 06:48 PM
Cogan John FrancisDirectorMar 16Option Exercise26.625,833155,24558,452Mar 20 01:28 PM
Cogan John FrancisDirectorMar 16Sale80.095,833467,13852,619Mar 20 01:28 PM
Cogan John FrancisDirectorMar 12Option Exercise26.625,833155,24558,452Mar 13 04:29 PM
Cogan John FrancisDirectorMar 12Sale80.935,833472,06552,619Mar 13 04:29 PM
MARTIN JOHN CExecutive ChairmanMar 01Option Exercise23.6050,0001,180,0003,067,762Mar 05 06:54 PM
Alton Gregg HEVP,Corporate &Medical AffairsMar 01Option Exercise40.5617,250699,66069,426Mar 05 07:04 PM
MOORE NICHOLAS GDirectorMar 01Option Exercise0.00178012,233Mar 05 08:42 PM
Alton Gregg HEVP,Corporate &Medical AffairsMar 01Sale78.6925,0001,967,31544,426Mar 05 07:04 PM
MARTIN JOHN CExecutive ChairmanMar 01Sale78.6550,0003,932,3753,017,762Mar 05 06:54 PM
Washington Robin LEVP, CFOFeb 28Sale80.315,000401,566105,405Mar 02 06:47 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 20Sale81.5414,4351,176,9920Feb 21 06:51 PM
YOUNG KEVINChief Operating OfficerFeb 10Option Exercise0.00908016,237Feb 13 04:58 PM
WILSON GAYLE EDirectorFeb 09Option Exercise26.6260,0001,596,900182,258Feb 13 05:24 PM
WILSON GAYLE EDirectorFeb 09Sale77.9260,0004,675,080122,258Feb 13 05:24 PM
MARTIN JOHN CExecutive ChairmanFeb 01Option Exercise23.6050,0001,180,0003,046,766Feb 05 08:38 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 01Option Exercise40.5617,250699,66062,738Feb 05 09:20 PM
YOUNG KEVINChief Operating OfficerFeb 01Option Exercise0.00620015,547Feb 02 09:14 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 01Sale83.5125,0002,087,86037,738Feb 05 09:20 PM
MARTIN JOHN CExecutive ChairmanFeb 01Sale83.5650,0004,177,8242,996,766Feb 05 08:38 PM